Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00891904 · OUTCOME

Grade 4-5 Toxicity as Assessed by NCI CTCAE v.30

Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer · Source last updated 2016-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Daily while on Treatment

Analysis population: Trial terminated early. Too few patients to analyze.

Groups in this outcome

Biological/Vaccine: Cetuximab

All patients enrolled will receive cetuximab 400 mg/m 2 IV x 1 dose 1 week prior to delivery of SBRT. Patients will then receive 15 Gy x 1 using SBRT and cetuximab i.v. 250 mg/m2 weekly for 4 weeks (total of 5 doses at 250 mg/m2).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Biological/Vaccine: Cetuximab0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
groups
  1. description
    All patients enrolled will receive cetuximab 400 mg/m 2 IV x 1 dose 1 week prior to delivery of SBRT. Patients will then receive 15 Gy x 1 using SBRT and cetuximab i.v. 250 mg/m2 weekly for 4 weeks (total of 5 doses at 250 mg/m2).
    id
    OG000
    title
    Biological/Vaccine: Cetuximab
population Description
Trial terminated early. Too few patients to analyze.
reporting Status
POSTED
time Frame
Daily while on Treatment
title
Grade 4-5 Toxicity as Assessed by NCI CTCAE v.30
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice